Propanc Biopharma, Inc.
PPCBHealthcare|Biotechnology|AU
$1.77
+0.13 (+7.93%)
DCF Value
$3.50
Tangible Book / Share
$83.67
Cash / Share
$7.40
Financials
Financial Snapshot
Market Cap
$1.8M
Enterprise Value
$1.5M
Revenue (TTM)
$0.00
Net Income (TTM)
-$18.9M
Cash & Investments
$832.0K
Net Cash
$322.9K
Free Cash Flow (TTM)
-$5.7M
Operating CF (TTM)
-$5.7M
Debt/Equity
0.05
Cash Runway & Burn Rate
Cash on Hand
$832.0K
Quarterly Burn
$1.4M
Monthly Burn
$474.0K
Est. Runway
~0.6 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $69.0K | $19.9K | $2.4K | $67.0K | $2.3K | $4.1K | $10.0K | $21.1K | $12.1K | $832.0K | $832.0K | |
| Operating Cash Flow | -$2.2M | -$2.2M | -$2.1M | -$1.8M | -$1.1M | -$1.4M | -$1.1M | -$935.1K | -$405.2K | -$5.7M | -$5.7M | |
| Free Cash Flow | -$2.2M | $0.00 | -$2.1M | -$1.8M | -$1.1M | -$1.4M | -$1.1M | -$935.1K | -$405.2K | -$5.7M | -$5.7M | |
| Capital Expenditure | $1.00 | $2.2M | -$2.9K | -$1.00 | $4.00 | $4.00 | $1.00 | -$2.00 | -$2.00 | -$4.9K | -$21.00 | |
| Financing Cash Flow | $2.2M | $2.4M | $2.1M | $1.9M | $1.1M | $1.5M | $1.1M | $941.9K | $490.8K | $6.5M | $6.5M |
R&D Spending
R&D (TTM)
$625.5K
R&D Intensity
—
R&D Growth vs Prior
+0.0%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $971.8K | $1.8M | $260.3K | $180.0K | $231.0K | $256.1K | $247.9K | $248.1K | $223.7K | $625.5K | $625.5K | |
| SG&A | $4.8M | $2.1M | $2.4M | $3.3M | $1.6M | $1.7M | $1.5M | $1.3M | $57.1M | $17.6M | $17.6M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $2.2K | $2.2K | $2.3K | $2.5K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | -$2.2K | -$2.2K | -$2.3K | -$2.5K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $971.8K | $1.8M | $260.3K | $180.0K | $231.0K | $256.1K | $247.9K | $248.1K | $223.7K | $625.5K | $625.5K | |
| SG&A | $4.8M | $2.1M | $2.4M | $3.3M | $1.6M | $1.7M | $1.5M | $1.3M | $57.1M | $17.6M | $17.6M | |
| Operating Income | -$5.7M | -$4.0M | -$2.6M | -$3.5M | -$1.8M | -$2.0M | -$1.8M | -$1.5M | -$57.3M | -$18.2M | -$18.2M | |
| Interest Expense | $3.2M | $2.8M | $1.3M | $1.7M | $449.5K | $568.8K | $532.8K | $665.8K | $563.8K | $430.5K | $430.5K | |
| Pretax Income | -$8.2M | -$7.2M | -$5.9M | -$4.9M | -$2.1M | -$2.7M | -$2.8M | -$1.9M | -$58.9M | -$18.9M | -$18.9M | |
| Net Income | -$7.9M | -$7.0M | -$5.8M | -$4.7M | -$2.0M | -$2.7M | -$2.7M | -$1.8M | -$58.9M | -$18.9M | -$18.9M | |
| EPS (Diluted) | -16816862437053444.00 | -2681095787476315.50 | -164533402928721.25 | -4811228.75 | -11959986968.33 | -738454474.53 | -26974080.43 | -0.02 | -3712.24 | -176.16 | -313.61 | |
| EBITDA | -$5.0M | -$4.4M | -$4.6M | -$3.1M | -$1.7M | -$2.1M | -$2.3M | -$1.3M | -$58.3M | -$18.4M | -$18.4M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 85.05 | 0.02 | 0.11 | 0.11 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $69.0K | $19.9K | $2.4K | $67.0K | $2.3K | $4.1K | $10.0K | $21.1K | $12.1K | $832.0K | $832.0K | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $82.0K | $60.9K | $91.1K | $69.0K | $6.6K | $15.0K | $19.0K | $25.4K | $8.4M | $8.5M | $8.5M | |
| Total Assets | $95.1K | $71.4K | $101.7K | $98.5K | $13.1K | $81.7K | $60.3K | $72.4K | $19.6M | $12.8M | $12.8M | |
| Total Current Liabilities | $5.5M | $6.8M | $4.4M | $3.7M | $3.1M | $3.1M | $3.2M | $3.8M | $5.6M | $3.4M | $3.4M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $58.6K | $105.6K | $23.8K | $0.00 | |
| Total Liabilities | $5.5M | $6.8M | $4.4M | $3.7M | $3.1M | $3.1M | $3.2M | $3.9M | $5.7M | $3.4M | $3.4M | |
| Stockholders' Equity | -$5.4M | -$6.8M | -$4.3M | -$3.6M | -$3.1M | -$3.0M | -$3.1M | -$3.8M | $13.9M | $9.4M | $9.4M | |
| Retained Earnings | -$38.2M | -$45.3M | -$51.0M | -$55.8M | -$58.2M | -$61.6M | -$64.7M | -$66.7M | -$125.6M | -$144.5M | -$144.5M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.2M | -$2.2M | -$2.1M | -$1.8M | -$1.1M | -$1.4M | -$1.1M | -$935.1K | -$405.2K | -$5.7M | -$5.7M | |
| Capital Expenditure | $1.00 | $2.2M | -$2.9K | -$1.00 | $4.00 | $4.00 | $1.00 | -$2.00 | -$2.00 | -$4.9K | -$21.00 | |
| Free Cash Flow | -$2.2M | $0.00 | -$2.1M | -$1.8M | -$1.1M | -$1.4M | -$1.1M | -$935.1K | -$405.2K | -$5.7M | -$5.7M | |
| Investing Cash Flow | $0.00 | $0.00 | -$2.9K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$4.9K | -$4.9K | |
| Financing Cash Flow | $2.2M | $2.4M | $2.1M | $1.9M | $1.1M | $1.5M | $1.1M | $941.9K | $490.8K | $6.5M | $6.5M | |
| Issuance of Stock | $464.3K | $0.00 | $1.1M | $450.0K | $0.00 | $99.3K | $24.7K | $23.1K | $0.00 | $7.3M | $5.5M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $1.7M | $2.4M | $1.0M | $1.5M | $282.0K | $766.5K | $590.3K | $918.8K | $755.4K | -$807.3K | -$824.6K | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $82.9K | $0.00 | $0.00 | $0.00 | $4.6M | $0.00 | $0.00 | |
| Net Change in Cash | $0.00 | $0.00 | $0.00 | $0.00 | -$64.8K | $1.8K | $6.0K | $11.0K | -$9.0K | $819.9K | $819.9K |
Dilution Tracker
Shares outstanding grew 55581330832.8% over 5 years — significant dilution
Shares Outstanding
1M
5-Year Share Growth
+55581330832.8%
Stock Issuance (TTM)
$5.5M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 85.05 | 0.02 | 0.11 | 0.11 | |
| Change vs Prior % | — | 461.2% | 1233.0% | 2815602870.6% | -100.0% | 2149.5% | 2448.9% | 73365544240.9% | -100.0% | 607.9% | 0.0% | |
| Stock Issuance | $464.3K | $0.00 | $1.1M | $450.0K | $0.00 | $99.3K | $24.7K | $23.1K | $0.00 | $7.3M | $5.5M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $82.9K | $0.00 | $0.00 | $0.00 | $4.6M | $0.00 | $0.00 |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 144.6% | 104.3% | 133.9% | 130.2% | 66.0% | 87.9% | 85.4% | 48.2% | -423.7% | -200.6% | -167.5% | |
| ROA % | -8275.0% | -9860.3% | -5664.4% | -4812.3% | -15464.5% | -3255.4% | -4410.2% | -2515.8% | -300.1% | -147.6% | -147.6% | |
| ROIC % | 270.1% | 175.4% | 93.4% | 158.8% | 71.9% | 98.4% | 65.9% | 50.7% | -366.4% | -192.4% | -183.5% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | -147.0% | -2.7% | -3.6% | -7.2% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 16.8% | 31.0% | 34.0% | -33.6% | 48.1% | -9.9% | 10.8% | 13.5% | -3628.9% | 68.3% | |
| Net Income | 16.4% | 10.5% | 18.2% | 17.7% | 57.3% | -31.2% | -0.1% | 31.6% | -3136.6% | 68.0% | |
| EPS (Diluted) | 53.6% | 84.1% | 93.9% | 100.0% | -248484.9% | 93.8% | 96.3% | 100.0% | -15679903.4% | 95.3% | |
| Operating Cash Flow | 55.2% | -1.2% | 5.4% | 10.2% | 38.1% | -25.4% | 23.0% | 15.4% | 56.7% | -1302.5% | |
| Free Cash Flow | 55.3% | 100.0% | 0.0% | 10.3% | 38.1% | -25.4% | 23.0% | 15.4% | 56.7% | -1302.5% | |
| R&D Expense | -32.8% | 87.9% | -85.7% | -30.9% | 28.3% | 10.9% | -3.2% | 0.1% | -9.8% | 179.6% | |
| SG&A Expense | -12.6% | -55.3% | 10.3% | 40.8% | -52.3% | 7.9% | -12.1% | -14.1% | 4329.9% | -69.2% | |
| Total Assets | -74.9% | -24.9% | 42.4% | -3.1% | -86.7% | 523.2% | -26.1% | 20.0% | 27028.9% | -34.9% | |
| Book Value / Share | -17.8% | 77.9% | 95.2% | 100.0% | -410469.6% | 95.6% | 96.0% | 100.0% | 1971687.5% | -90.5% | |
| Debt | 212.1% | 34.0% | -65.8% | -3.5% | -54.7% | 53.0% | -47.5% | 73.7% | 82.1% | -97.2% | |
| Diluted Shares | 80.1% | 461.2% | 1233.0% | 2815602870.6% | -100.0% | 2149.5% | 2448.9% | 73365544240.9% | -100.0% | 607.9% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.02
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$3.50
Tangible Book / Share
$83.67
Net Current Assets / Share
$5.00
Cash / Share
$7.40
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.43 | -0.15 | -0.33 | -12159.06 | -0.06 | -0.08 | -0.08 | -823653.64 | -0.28 | -0.09 | -0.01 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -0.63 | -0.16 | -0.44 | -15829.71 | -0.05 | -0.08 | -0.08 | -438835.20 | 1.18 | 0.18 | 0.02 | |
| EV/EBITDA | -1.35 | -1.27 | -0.76 | -18448.92 | -0.49 | -0.60 | -0.34 | -1313923.03 | -0.31 | -0.05 | -0.08 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-19.78
Distress
Piotroski F-Score
3
Weak